NEW YORK (GenomeWeb) – Belgian MDx Firm Biocartis announced today that it has received a €1.4 million ($1.5 million) grant from the Flemish Agency for Innovation by Science and Technology (IWT) to support the development of liquid biopsy versions of its solid tumor BRAF and KRAS diagnostics for melanoma and colorectal cancer.

The funds, made as part of an IWT-subsidized collaboration project called Early Diagnosis by Easy Sampling, will also support more general research on improved liquid biopsy methodologies, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.